Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Which way now for TKIs in EGFR mutation-positive lung cancer?

EGFR tyrosine kinase inhibitors (TKIs) are established first-line treatments for EGFR mutation-positive non-small-cell lung cancer (NSCLC) but their optimum use continues to be explored
18 Dec 2016
Lung and other thoracic tumours

Yesterday’s Proffered Paper session featured results from first-line studies with the potential to influence the application of these agents in practice. In the overall survival analysis of the phase IIb LUX-Lung 7 trial (with a median follow-up of 42.6 months), afatinib improved survival compared with gefitinib (median 27.9 months versus 24.5 months), although the difference was not significant (hazard ratio 0.86; p=0.258) (Abstract 440O).

The effect, said Li Zhang (Sun-Yat-sen University Cancer Center, Guangzhou, China), was consistent across del19 and L858R mutation subtypes. In line with the primary analysis,1 updated progression-free survival, time-to-treatment failure and overall response analyses significantly favoured afatinib and the adverse event (AE) profiles were unchanged. Combining erlotinib with the anti-PD-L1 antibody atezolizumab, in an effort to prolong TKI response, was associated with manageable safety in a phase Ib study of 28 patients, according to Brigette Ma (The Chinese University of Hong Kong, Shatin, China) (Abstract 441O).

Altogether, 39% of patients had treatment-related grade 3–4 AEs and five receiving atezolizumab discontinued due to AEs. There was no pneumonitis. Efficacy was promising, with response and disease control rates of 75% and 90%, respectively, among 20 patients with EGFR mutation-positive NSCLC.

1. Park K, et al. Lancet Oncol 2016;17:577–89

This article appeared in the Sunday 18 December 2016 edition of the Congress Highlights.

Last update: 18 Dec 2016

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings